Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Citation: Boominathan, Insights into Weight loss therapy: CDX2 inhibits hepatic steatosis and promotes weight loss via down regulation of Nocturnin, 27/February/2015, 8.56 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Web: http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
Significance: CDX2, by increasing the expression of its target gene, it may decrease the expression of Nocturnin, and promote weight loss. Thus, pharmacological formulations encompassing “CDX2 activators“ may be used to promote weight loss.
Undisclosed information: How CDX2 suppresses the expression of Nocturnin
Amount: $300*
* Research cooperation
